The clinical application of Arthrosamid® (iPAAG) is safe and effective.
Stable and statistically significant change on all WOMAC subscales and WOMAC total over the 56 week observation period.
Statistically significant reduction in pain maintained at 3 years.
79% response rate with the under 70-year-olds.
Significant difference in change from baseline between Arthrosamid® and Synvisc-One® at 52 weeks.
IDA 12 Months Study - Poster 336 presented at OARSI Connect 2021
IDA 2-Year Study - OARSI 2022 Poster 493
ROSA 12 Months Study - OARSI 2022 Poster 491